The association between hypertension and an increased risk for Alzheimer's disease (AD) and dementia is well established. Many data suggest that modulation of the renin-angiotensin system may be meaningful for the prevention and therapy of neurodegenerative disorders, in particular AD. Proteolytic cleavage of the amyloid precursor protein (APP) by asecretase precludes formation of neurotoxic Ab peptides and is expected to counteract the development of AD. An established approach for the upregulation of a-secretase cleavage is the activation of G protein-coupled receptors (GPCRs). Therefore, our study aimed to analyze whether stimulation of angiotensin AT 1 or AT 2 receptors stably expressed in HEK cells influence the nonamyloidogenic pathway of APP processing. Treatment of both receptors with angiotensin II clearly showed that only activation of the AT 1 receptor increased several fold the a-secretase-mediated shedding of APP. This effect was completely abolished by treatment with the AT 1 receptor-specific antagonist telmisartan. Using the BIM-46187 inhibitor, we demonstrate that the Gaq protein-mediated pathway is involved in this stimulation process. Stimulation of AT 1 receptors with the b-arrestinbiased agonist SII was ineffective regarding a-secretase-mediated APP shedding. This result discloses that only the G protein-dependent pathway is involved in the Ang II-induced APP shedding. Blocking of Gbc subunits by the inhibitor gallein completely prevented constitutive and Ang IIinduced APP shedding. Our findings provide evidence that induction of APP shedding via Ang II/AT 1 receptor stimulation is effected by G protein activation with Gbc subunits playing important roles.
Introduction
The accumulation of amyloid b peptides (Ab) in the brain is a central event leading to the development of AD [1] . Ab peptides are derived from the amyloid precursor protein (APP) by sequential proteolytic cleavage through b-and c-secretases (amyloidogenic pathway). In the alternative nonamyloidogenic pathway, APP is cleaved within the Ab domain by the a-secretase [2] . This cleavage precludes the formation of amyloidogenic peptides and leads to the release of soluble N-angiotensin system (RAS) is an important regulator of blood pressure and plays a role not only in the cardiovascular system but also in the central nervous system. The RAS is a peptide hormone system composed of various enzymes, peptides, and receptors which, by regulating blood pressure and fluid homeostasis, plays an important role in cardiovascular physiology. The RAS exists also as an endogenous brain system and many studies have shown an association between hypertension and an increased risk for AD and dementia [7] [8] [9] .
Changes in the RAS have been widely observed in AD brains. By using a tritium-labeled ACE inhibitor an increased angiotensin-converting enzyme (ACE) density in AD brains has been detected [10] . Furthermore, the up-regulation of AT 2 receptors in ADaffected brain hypocampus samples has been identified after applying a combination of a 125 I-labeled AT 1/2 receptor ligand and AT receptor-specific antagonists [11] . Detection of AT receptors with receptor-specific ligands is superior in comparison to their immunohistochemical detection because commercial anti-AT receptor antibodies are mostly unspecific [12, 13] .
A potential relationship between ACE and AD can also be deduced from human genetic studies. An insertion/deletion polymorphism within intron 16 of the ACE gene associates with AD [14] where the insertion allele is associated with an increased risk for AD [15] .
Taken together, RAS seems to be misregulated in AD brains. In further studies using postmortem tissues and cerebrospinal fluid (CSF) of human AD cases and control material, brain ACE level and activity was found to be elevated in AD cases [16] .
Angiotensin-converting enzyme is known to be able to degrade AD-related Ab petides [17] and therefore an up-regulation in the brain, as a protective mechanism against the development of AD, is imaginable.
Currently, pharmacological inhibition of the RAS is a major therapeutic strategy used to manage hypertension and to reduce the risks of cardiovascular complications [18] . Angiotensin II (Ang II) binds to two major receptors of RAS, the AT 1 receptor (Ang II type 1 receptor) and the AT 2 receptor (Ang II type 2 receptor). Both receptors are members of the G protein-coupled receptor (GPCR) family and angiotensin peptides are natural ligands of these receptors.
The AT 1 receptor is a key regulator of blood pressure and body fluid homeostasis. A majority of the cardiovascular, renal, and adrenal actions of Ang II are mediated by the AT 1 receptor. However, overactivity of the AT 1 receptor is observed in various pathologies such as atherosclerosis, diabetes, and AD, and is associated with hypertension, brain inflammation, autoimmune disorders, and cognitive loss.
Today, potent and selective AT 1 receptor antagonists [known as angiotensin receptor blockers (ARBs)] are extensively used for the treatment of hypertension and an increasing number of studies in humans and animals have shown that ARBs also ameliorate risk factors for AD and have neuroprotective properties [9, 19] .
Angiotensin receptor blockers have been found to be anti-inflammatory compounds, reducing apoptosis [20] and in addition, promote hippocampal synaptic signaling [21] . It was also shown in an AD mouse model that AT 1 receptor deficiency significantly decreases brain Ab generation and deposition by regulating c-secretase complex formation [22] .
The neuroprotective effects of ARBs have been widely demonstrated in vivo, using rodent models of AD. Intracerebroventricular (ICV) administration of Ang II promotes Ab production in Sprague-Dawley rats and this effect could be completely abolished by concomitant ICV AT 1 antagomist losartan infusion [23] . In experiments with mouse models of AD, by using different ARBs (telmisartan, losartan, valsartan, or olmesartan), significant prevention of cognitive decline was observed [24] [25] [26] [27] . However, controversial results were obtained regarding Ab accumulation. In some studies, decreased Ab accumulation was observed [24, 28] in other studies no effect on Ab was reported [26, 29, 30] . In a large human brain autopsy study it was found that medication with ARBs may reduce amyloid deposition in the brain [31] .
However, in spite of many data from in vitro and in vivo investigations not much is known about the direct influence of angiotensin receptor activation on APP processing and about the mode of action of ARBs in lowering b-amyloid peptides.
Induction of the nonamyloidogenic pathway of APP processing can be achieved by the activation of different GPCRs, such as muscarinic acetylcholine [32] , serotonin [33] , or PACAP [34] receptors. We and others have shown that the activation of GPCRs coupled with phospholipase C, calcium signaling, and protein kinase C caused induction of protein shedding [32, 35, 36] . As the AT 1 receptor is also coupled through G proteins with the activation of this signaling pathway [37, 38] , we hypothesized that the activation of the AT 1 receptor might also induce protein shedding. To better understand the mode of action of ARBs and the direct effect of RAS activation on APP processing, we investigated the impact of AT 1 and AT 2 receptor stimulation on the nonamyloidogenic pathway of APP processing. Furthermore, we analyzed the participation of Ga and Gbc subunits in the constitutive and Ang IIinduced a-secretase cleavage of APP.
Results
Influence of the activation of angiotensin receptors on the a-secretase-mediated shedding of APP To elucidate the impact of the RAS modulation via angiotensin receptors, AT 1 and AT 2 , on APP proteolytic processing, we investigated the influence of selective receptor activation on the a-secretase-induced shedding of APP. For this study, we used HEK cells stably expressing either the AT 1 receptor (AT 1 cells) or the AT 2 receptor (AT 2 cells). Both cell lines were previously well characterized regarding angiotensin receptors by ligand-binding studies [39] . To determine whether the stimulation of angiotensin receptors influence the a-secretase cleavage of APP, cells were incubated for 4 h with Ang II or other peptides as indicated (Fig. 1) . The amount of released sAPPa in peptide-stimulated cells was compared with the amount found in unstimulated (solvent treated) cells.
Treatment of AT 1 cells with Ang II resulted in the activation of a-secretase cleavage of APP. An Ang II dose-dependent induction of sAPPa production was observed. Treatment with 10 lM Ang II caused a several-fold increase in the sAPPa release (Fig. 1A) . On the other hand, treatment of untransfected HEK cells with the equal Ang II concentration had no influence on the a-secretase-mediated APP shedding (Fig. 1B) .
To confirm that the Ang II-induced production of sAPPa was the result of AT 1 receptor activation, cells were incubated with the AT 1 receptor-specific antagonist telmisartan [40] . Simultaneous incubation with Ang II (10 lM) and telmisartan (10 lM) caused complete inhibition of the Ang II-stimulated sAPPa secretion (Fig. 1C) .
To examine whether Ang II treatment affected the expression of the APP holoprotein, the AT 1 receptor, and the potential a-secretases, ADAM 10 and ADAM 17, membranes prepared from control and from Ang II-treated cells were analyzed by PAGE and western blot. Treatment of AT 1 cells with 10 lM Ang II for 4 h increased the expression of the AT 1 receptor but did not affect the expression level of APP, ADAM 10 and ADAM 17 ( Fig. 1D) . Therefore, the increase in sAPPa amounts after Ang II stimulation is not caused by an enhanced protein expression of potential a-secretases or their substrate. Ang II can be converted stepwise by aminopeptidases to the heptapeptide Ang III and then to the hexapeptide Ang IV or by the angiotensin-converting enzyme 2 to Ang (1-7). All these peptides are biologically active and are ligands for several angiotensin receptors. Ang III binds with high affinity to AT 1 and AT 2 receptors. Ang IV exhibits low affinity to AT 1 and AT 2 receptors, but high affinity to the AT 4 receptor subtype. Ang (1-7) is a ligand for AT 2 and Mas 1 receptors but does not bind to the AT 1 receptor [39, 41] . Therefore, we proved whether Ang II metabolites are also involved in the activation of the a-secretase cleavage of APP. AT 1 cells were incubated with different Ang II metabolites. Treatment with Ang III increased sAPPa release to the same extent (above threefold) as Ang II did. Ang IV treatment caused a slightly reduced induction of sAPPa release (above two-fold) as compared to Ang II, and Ang (1-7) had no influence on the a-secretase cleavage of APP in AT 1 cells (Fig. 2) .
As Ang II also binds with high affinity to the AT 2 receptor, the influence of AT 2 receptor activation on APP shedding was analyzed. However, treatment of AT 2 cells with Ang II or AT 2 receptor-potent and selective agonist CGP42112 had no influence on the sAPPa release (Fig. 3A,B ). Due to this unexpected observation, we analyzed AT 2 cells for AT 2 receptor expression and localization. We detected AT 2 receptors localized in the membrane protein fraction of AT 2 cells by immunoblotting ( Fig. 3C ) and on the plasma membrane via immunfluorescence microscopy ( Fig. 3D ). Taken together these results indicate that the AT 2 receptor is not involved in the modulation of a-secretase cleavage of APP.
The ADAM 10 metalloproteinase is responsible for constitutive and induced APP shedding [42, 43] , therefore we analyzed whether this enzyme is also involved in the Ang II/AT 1 receptor-induced APP shedding. Cells were either treated with the broad-spectrum metalloproteinase inhibitor GM6001 (10 lM) or the ADAM 10 preferential inhibitor GI254023X (10 lM). A strong decrease in constitutive and~50% Ang IIinduced APP shedding was observed with both inhibitors (Fig. 4) . Inhibition with GI254023X indicates an involvement of ADAM 10 in Ang II/AT 1 receptor-induced APP shedding. Treatment of HEK cells with the GI254023X or GM6001 inhibitor did not affect the expression level of APP, ADAM 10, or ADAM 17 [35] .
Analysis of the AT 1 receptor signaling pathways involved in the Ang II-induced a-secretase shedding of APP In the majority of tissues, the AT 1 receptor is coupled through Gaq with the activation of phospholipase C, calcium, and protein kinase C signaling [37, 38] . By applying Ga and Gbc selective inhibitors, we elucidated the involvement of these pathways in the Ang II-induced APP shedding.
The small molecule BIM-46187 was identified as a cell-permeable Gaq-preferring inhibitor. BIM blocks agonist function of GPCRs by freezing Gaq in the empty pocket conformation by permitting GDP exit but interdicting GTP entry [44] . We used this inhibitor to establish the participation of Gaq in the induction As a control, cells were treated with equivalent amounts of solvent (water). Then sAPPa was detected and quantified by western blotting as described in Fig. 1 . For quantitation, the experiments were repeated at least in three independent experiments performed in duplicate. Shown are the mean effects AESD. Significance was determined by the one-way ANOVA Bonferroni test (***P < 0.001, ns: not significant).
of sAPPa release via Ang II/AT 1 activation. Treatment of cells with 10 and 50 lM BIM-46187 caused a~50% reduction in the Ang II-induced sAPPa production but had no influence on the constitutive sAPPa release (Fig. 5A ).
As the BIM-46187 inhibitor might block other Ga subunits [45] , cells were treated with the selective Gas inhibitor NF449. Inhibition of the Gas subunit did not have any influence neither on the constitutive (Fig. 5B ) nor on the Ang II-induced sAPPa release (Fig. 5C ). Thus, it seems that only the Gaq subunit participates in the Ang II-induced induction of APP shedding. However, both subunits, Gaq and Gas, had no influence on the constitutive sAPPa production.
The partial inhibition of the Ang II-induced APP shedding, also after applying the higher BIM-46187 concentration suggested, that not only the Gaq protein-mediated pathway was involved in the stimulation of this process. Recent studies have revealed that the AT 1 receptor is also capable of activating G proteinindependent signaling that is mediated by b-arrestin. Stimulation of the AT 1 receptor with the Ang II analog SII ([sarcosine 1 , Ile 4 , Ile 8 ] Ang II) selectively activates AT 1 receptor -b-arrestin-mediated signaling (barrestin-biased agonist) but fails to activate classical G protein signaling [46, 47] . To prove whether the AT 1 receptor-b-arrestin signaling participates in the Ang IIinduced a-secretase-mediated APP shedding, AT 1 cells were treated with Ang II or with b-arrestin-biased agonist SII peptide. Treatment with Ang II resulted in a several-fold increase in sAPPa release but activation of the AT 1 receptor with an increased concentration (5-50 lM) of SII peptide had no influence on the sAPPa production (Fig. 5D ). As the AT 1 receptor b-arrestinmediated signaling induced ERK activation [47] , we checked whether treatment of AT 1 cells with SII peptide resulted in ERK activation. As expected, stimulation with SII peptide caused ERK phosphorylation (Fig. 5E) , which approved the activation of the barrestin-mediated signaling. These results clearly show that solely the G protein-dependent pathway is involved in the Ang II-induced a-secretase APP shedding. G protein-coupled receptors transmit signals through heterotrimeric G proteins composed of Ga and Gbc. The role of Ga in signal transduction is well established. There is also much evidence that Gbc subunits can modulate many effectors via direct interaction and can activate various intracellular signaling pathways [48] . A compound such as gallein blocks interactions between Gbc, but not Ga with effectors [49] . To test the involvement of Gbc subunits in APP shedding, cells were treated with gallein (10-50 lM).
Both, the constitutive and Ang II-induced release of sAPPa were blocked in a dose-dependent manner by gallein treatment. Surprisingly, the constitutive APP shedding was almost completely inhibited by treatment with 50 lM gallein (Fig. 6A) . A strong inhibition of Ang II-induced sAPPa release was also observed (Fig. 6B) . To exclude the influence of the AT 1 receptor on the constitutive APP shedding, nontransfected HEK cells were also treated with gallein. A similar concentration-dependent inhibition of sAPPa production was also observed (Fig. 6C) . Treatment of AT 1 cells with gallein did not affect the expression levels of APP, ADAM 10, and ADAM 17 (Fig. 6D) . These results indicate that free Gbc subunits are involved in the modulation of constitutive and Ang II-induced asecretase shedding of APP. Presented data demonstrate that induction of APP shedding via Ang II/AT 1 receptor stimulation is an effect of G protein activation and that Gbc subunits strongly contribute to this event.
Discussion
Angiotensin receptor blockers exhibit beneficial effects regarding neuroprotection and Alzheimer 0 s disease. We therefore aimed to study the possible role of angiotensin receptors in nonamyloidogenic, a-secretasemediated APP processing. Since AT 1 receptor signaling is conducted by G proteins and b-arrestin, we also elucidated the impact of Ga and Gbc subunits as well as b-arrestin on a-secretase-mediated APP shedding.
Studies in rodent models of AD have shown that ARBs have neuroprotective properties and might be used for the prevention and treatment of Alzheimer's disease. Reduction in the Ab level was observed after AT 1 receptor blocking with ARBs which selectively prevent the actions of Ang II on AT 1 receptors [24] . Additionally, the central injection of Ang II promotes Ab production in rats [23] . These data indicate that Ang II, a key player in hypertension, also has an important role in AD development.
On the other hand, there is much evidence from animal experiments, that the induction of the nonamyloidogenic processing of APP had beneficial effects against AD [5, 6, 50] . Our results clearly demonstrate that AT 1 receptor stimulation via Ang II and its metabolites induced the nonamyloidogenic processing of APP (Figs 1 and 2) . Specificity of this effect was confirmed by selective blocking of the AT 1 receptor with telmisartan (Fig. 1C) . Stimulation of the AT 2 receptor had no influence on the a-secretase shedding of APP (Fig. 3) . The latter result was surprising to us since AT 2 receptor up-regulation has been observed in AD brains [11] . The biological role and the signaling mechanism of the AT 2 receptor are still very poorly understood [51, 52] and therefore our observation cannot be assigned to a specific signaling cascade in HEK cells. However, our data do not exclude a possible Fig. 4 . Effect of hydroxamate metalloproteinase inhibitors on Ang II-induced a-secretase cleavage of APP. AT 1 cells were first preincubated for 60 min with inhibitor (10 lM GM6001 or GI254023X as indicated), and then medium was replaced by serum-free medium containing 10 lM Ang II and inhibitor. As a control, cells were treated with equivalent amounts of solvent (DMSO). After 4 h, medium was collected, and released sAPPa was identified as described in Fig. 1 . For quantification the experiments were repeated at least in three independent experiments performed in duplicate. Shown are the mean effects AESD. Significance was determined by the one-way ANOVA Bonferroni test (**P < 0.01, ***P < 0.001).
contribution of the AT 2 receptor in regulation of APP processing in neuronal cells or in vivo.
Activation of the AT 1 receptor is coupled with two major signaling pathways: to Gaq stimulating the PLC-PKC pathway and to b-arrestin 2-mediated signaling.
Elucidation of the mode of action of Ang II via the AT 1 receptor on APP processing clearly revealed that only the G protein-dependent pathway is involved in the induction of Ang II-induced a-secretase-mediated APP shedding. Inhibition of the Gaq subunit resulted in significant impairment of the Ang II-induced sAPPa release. On the other side, treatment with b-arrestinbiased agonist SII, which selectively activates G proteinindependent b-arrestin signaling had no influence on the sAPPa release (Fig. 5) . Similar results were obtained by a study regarding induction of the a-secretase-mediated APP processing via serotonin receptor stimulation. It was demonstrated by using serotonin 5-HT 4d receptor mutants deficient in either G protein or b-arrestin signaling, that only the G protein pathway was involved in the induction of sAPPa release. The mutant receptor deficient in G protein signaling caused a significant down-regulation of sAPPa production but the mutant receptor deficient in b-arrestin recruitment maintained the ability to stimulate sAPPa release after agonist treatment [53] .
In contrast to b-arrestin 2-mediated signal transduction selective inhibition of the Gaq subunit resulted in significant impairment of the Ang II-induced sAPPa release. The used inhibitor prevents GTP binding to the Ga subunit and therefore impedes dissociation and activation of heterotrimeric G proteins. Therefore, the effect of the Gaq inhibitor on APP shedding may also be caused by lacking G protein bc-subunit signaling.
Both subunits (Ga and Gbc) interact with effector molecules and activate various intracellular pathways. Gbc does not have a catalytic site and therefore interplays with effectors through protein-protein interaction. Gbc subunits can modulate a variety of effectors, and then the medium was replaced by serum-free medium containing the indicated concentration of an inhibitor and/or 10 lM Ang II. As a control, cells were treated with equivalent amounts of solvent (DMSO). After 4 h, the medium was collected, and released sAPPa was detected and quantified as described in Fig. 1. (B,C) Role of the selective Gas inhibitor NF449 on the constitutive (D) and Ang II-induced (E) sAPPa release. Cells were treated as described in (A) with the exception of NF 449 being used instead of the BIM inhibitor. (D) Influence of biased agonist SII peptide on the sAPPa release. AT 1 cells were incubated for 4 h with either 10 lM Ang II, SII (5-50 lM), or H 2 O (control). Then, sAPPa was detected and quantified by western blotting as described in Fig. 1 . For quantitation the experiments were repeated at least in three independent experiments performed in duplicate. Shown are the mean effects AESD. Significance was determined by the oneway ANOVA Bonferroni test (***P < 0.001). (E) SII peptide-stimulated ERK activation in AT 1 cells. Cells were cultured in serum-free medium for 4 h and then stimulated with 30 lM SII peptide for 5 min. Phosphorylation of ERK was analyzed in cell lysates by immunoblotting and detected with a phospho-ERK 1/2-specific antibody (top blots) and a ERK 1/2-specific antibody (bottom blots).
for example, various kinases, adenylyl cyclases, phospholipase Cb, and several ion channels. Compounds such as gallein block interactions between Gbc and effectors [48] . We found that Gbc subunits strongly participate in the modulation of a-secretase-mediated shedding of APP. Treatment with the Gbc inhibitor gallein significantly reduced constitutive and Ang IIinduced sAPPa release. Especially the strong inhibition of the constitutive APP shedding points out, that Gbc complexes play important roles as a-secretase modulators. Several GPCRs coupled with various Ga subunits have been described as activators of a-secretasemediated APP shedding [54] . Stimulation of each receptor causes increased levels of Ga and of Gbc complexes where Gbc either by direct or indirect interaction, might activate a-secretases.
Remarkably, the APP a-secretases ADAM 10 and ADAM 17 are also responsible for ectodomain shedding of ACE 2 [55, 56] . Our data suggest that the activation of the AT 1 receptor via angiotensin peptides might also modulate the ratio of membrane-bound and soluble ACE forms and by this way influence the RAS function.
Humans express 5 distinct Gb and 12 Gc subunits [57] which can pair to form unique Gb x c x combinations. Further research should focus on the identification and role of specific Gb x c x dimers in nonamyloidogenic APP and ACE 2 processing.
Our results raise the question why -on one handAng II via the AT 1 receptor increases nonamyloidogenic processing of APP and -on the other handblocking of this receptor with ARBs results in the reduction of Ab levels.
Recently, two groups have shown that b-arrestin 1 and 2 induce generation of Ab peptides by increasing the catalytic activity of the c-secretase complex and that the expression of b-arrestin in the brain is elevated in individuals with AD [58, 59] . It was also found that two GPCRs (GPR3 and b 2 -adrenergic receptor) implicated previously in AD, mediate their effects on Ab generation through interaction with b-arrestin 2 [59] . Additionally, in vivo studies -where AT 1 receptors were stimulated by central (intracerebroventricular) Ang II infusion -demonstrated elevated production of Ab, C99, and C83 APP fragments and significant enhancement of c-secretase activity [23] . The activation of b-arrestin 2 signaling after AT 1 receptor stimulation was probably the reason for the increased Ab production. An increased level of the C83 APP fragment mirrors induction of the a-secretase shedding of APP [43] and therefore our results are not contrary to this in vivo study. It seems that the activation of the AT 1 receptor via Ang II in the brain stimulates both: amyloidogenic (b-arrestin-mediated signaling) and nonamyloidogenic (G protein-mediated signaling) pathways of APP, with a clear shift to the amyloidogenic pathway. Therefore, blocking of the AT 1 receptor with ARBs leads to reduced Ab production. Our data obtained with cultured cells on the other hand suggest that activation of the AT 1 receptor via a G protein-biased agonist which selectively activates only G protein pathways and simultaneously prevents b-arrestin signaling will activate only the nonamyloidogenic pathway. Such biased agonists are probably as effective as ARBs for prevention and treatment of AD. However, our finding requires further investigation and should be confirmed in in vivo experiments with mouse models of AD by using biased ligands activating only selective G protein or arrestin pathways.
Materials and methods

Antibodies and reagents
The following antibodies were used: mouse IgG 6E10 detecting sAPPa and full-length APP (Covance, Princeton, NJ, USA); Anti-ADAM 10 (AB19026) and ADAM 17 (AB19027) antibodies directed against cytosolic ADAM domains were from Millipore, antihemagglutinin mouse antibody 16B12 were from HiSS Diagnostics. Secondary anti-rabbit and anti-mouse peroxidase-coupled antibodies were from Sigma-Aldrich (Taufkirchen, Germany). The inhibitors applied: GM6001 (broad-spectrum metalloproteinase inhibitor) was from Calbiochem and GI254023X (a preferential ADAM 10 inhibitor) was a kind gift from Prof. Husmann (University Mainz, Germany); telmisartan was from Sigma-Aldrich; gallein and NF449 from Tocris Bioscience (Bristol, UK). BIM-46187 was prepared as described [44] . All peptides were from Bachem. All other chemicals were either from Merck Biosciences or SigmaAldrich.
Stimulation of the a-secretase cleavage of APP Cell lines HEKAT 1 (stably expressing the rat hemagglutinin-tagged AT 1 receptor) and HEKAT 2 (stably expressing the rat hemagglutinin-tagged AT 2 receptor) were grown in DMEM supplemented with 10% fetal calf serum (FCS).
All cells were grown nearly to confluence on 10 cm or 6 cm dishes coated with poly-L-lysine. After washing (39) with serum-free DMEM, cells were incubated for 4 h with indicated peptide concentration and serum-free DMEM containing fatty acid-free BSA (10 lgÁmL À1 ). Then, the medium was collected and analyzed for sAPPa as described below. In experiments with inhibitors, cells were first preincubated for 30 min with the indicated inhibitor, followed by treatment of the cells as described above.
Immunoblot analysis
Proteins of the cell culture supernatant, after precipitation with 10% (v/v) trichloroacetic acid (TCA) or of cell membranes, were separated by 10% SDS/PAGE and blotted onto nitrocellulose membranes. Membranes were probed by applying protein-specific antibodies followed by appropriate secondary antibodies. The specific bands were detected by chemiluminescence using the VersaDoc system (Bio-Rad Laboratories, Munich, Germany) and quantified via the AIDA 4.25 software (Raytest, Straubenhardt, Germany). For comparative and quantitative analysis, effects observed with solvent-treated cells were used as a control and were set to 100%. The protein content of each cell culture dish was determined by the Bradford method, and the values of the specific protein bands from the cell culture supernatant were normalized to the protein amount. For the analysis of the membrane proteins, aliquots containing 20 lg of cell membrane proteins were separated by 10% SDS/PAGE gels, blotted onto nitrocellulose membranes and analyzed as described above.
Cell membrane preparation
Cells were suspended in buffer (20 mM HEPES, pH 7.4) at 4°C, then sonicated for 20 s, and centrifuged at 100 000 g for 1 h at 4°C. The pellet was resuspended in the same buffer, sonicated, and centrifuged in the same condition. The membrane pellet was resuspended in 20 mM HEPES, pH 7.4, and stored at À80°C. Protein content was determined by the Bradford method.
Extracellular signal-regulated kinase activity
The kinase activity of extracellular signal-regulated kinase (ERK) was measured using the MAPK assay kit (Cell Signaling Technology) according to the manufacturer's protocol.
Confocal microscopy
Cells were grown on cover slips, fixed with 4% paraformaldehyde and permeabilized with 0.05% Triton X-100. After incubation with anti-HA antibody (16B12) cells were stained for visualization of AT2 receptors with a Cy3-coupled anti-mouse IgG. Microscopy was performed on a Leica TCS SP confocal microscope.
Statistical analysis
The results are expressed as percentage relative to control (unstimulated cells) and represent mean values AE SD of at least three independent experiments performed in duplicate. Unstimulated cells were treated with equivalent amounts of solvent. Statistical significance between control cells and treated cells was determined by using the one-way ANOVA/Bonferroni post hoc test analysis or the unpaired Student's t-test (*P < 0.05, **P < 0.01, ***P < 0.001).
